A phase II trial of GDC-0084 for Glioblastoma.
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2017
At a glance
- Drugs GDC 0084 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
- 22 Aug 2017 According to a Novogen media release, the company expects to initiate this trial in the fourth quarter of 2017. Consultation with FDA expected to occur prior to initiation of the study to discuss key features of the clinical trial design.
- 11 Nov 2016 New trial record